Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:PRVB

Provention Bio (PRVB) Stock Price, News & Analysis

Provention Bio logo

About Provention Bio Stock (NASDAQ:PRVB)

Key Stats

Today's Range
$24.98
$25.00
50-Day Range
$23.74
$24.98
52-Week Range
$3.18
$25.00
Volume
9.12 million shs
Average Volume
2.28 million shs
Market Capitalization
$2.37 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.

Receive PRVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Provention Bio and its competitors with MarketBeat's FREE daily newsletter.

PRVB Stock News Headlines

Macrogenics Inc MGNX
2 sentences that change everything you THOUGHT you knew about trading
If you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfast... go to work... But if you say these two sentences to your broker... you could collect as much as $1,250 on Friday... no matter where you live, whether you're working or already retired. It all has to do with a unique stock market secret that's worked 97% of the time for the past 8 years running.
Sanofi completes Provention Bio acquisition
See More Headlines

PRVB Stock Analysis - Frequently Asked Questions

Provention Bio, Inc. (NASDAQ:PRVB) issued its quarterly earnings data on Thursday, November, 4th. The company reported ($0.43) earnings per share for the quarter, beating analysts' consensus estimates of ($0.51) by $0.08. The firm earned $0.68 million during the quarter, compared to analyst estimates of $3.75 million. Provention Bio had a negative trailing twelve-month return on equity of 103.36% and a negative net margin of 880.69%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Provention Bio investors own include NVIDIA (NVDA), NIO (NIO), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Meta Platforms (META), VBI Vaccines (VBIV) and Amarin (AMRN).

Company Calendar

Last Earnings
11/04/2021
Today
11/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PRVB
Fax
N/A
Employees
82
Year Founded
N/A

Profitability

Net Income
$-113,570,000.00
Net Margins
-880.69%
Pretax Margin
-984.54%

Debt

Sales & Book Value

Annual Sales
$12.90 million
Book Value
$1.40 per share

Miscellaneous

Free Float
82,365,000
Market Cap
$2.37 billion
Optionable
Not Optionable
Beta
2.47
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

This page (NASDAQ:PRVB) was last updated on 11/5/2024 by MarketBeat.com Staff
From Our Partners